For the quarter ended June 2024, Idexx Laboratories (IDXX Quick QuoteIDXX - Free Report) reported revenue of $1 billion, up 6.4% over the same period last year. EPS came in at $2.44, compared to $2.67 in the year-ago quarter.

The reported revenue represents a surprise of +0.11% over the Zacks Consensus Estimate of $1 billion. With the consensus EPS estimate being $2.87, the EPS surprise was -14.98%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Idexx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Companion Animal Group- United States

  : $628.68 million versus $637.35 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change.

• Revenue- Companion Animal Group- International

  : $293.61 million versus the two-analyst average estimate of $282.88 million. The reported number represents a year-over-year change of +7.8%.

• Revenue- LPD- International

  : $25.19 million compared to the $24.42 million average estimate based on two analysts. The reported number represents a change of -1.2% year over year.

• Revenue- Water- International

  : $22.27 million versus $22.92 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2% change.

• Revenue- Companion Animal Group (CAG)

  : $922.30 million compared to the $923.58 million average estimate based on four analysts. The reported number represents a change of +6.4% year over year.

• Revenue- Other

  : $4.25 million compared to the $4.07 million average estimate based on four analysts. The reported number represents a change of +5.2% year over year.

• Revenue- Livestock and poultry diagnostics (LPD)

  : $30.31 million compared to the $29.98 million average estimate based on four analysts. The reported number represents a change of +1.3% year over year.

• Revenue- Water

  : $46.73 million compared to the $45.93 million average estimate based on four analysts. The reported number represents a change of +8.6% year over year.

• Revenue- IDEXX VetLab consumables

  : $325.35 million compared to the $324.54 million average estimate based on three analysts. The reported number represents a change of +7.1% year over year.

• Revenue- CAG Diagnostics capital- instruments

  : $35.29 million versus the three-analyst average estimate of $34.87 million. The reported number represents a year-over-year change of +3.6%.

• Revenue- CAG-Reference laboratory diagnostic and consulting services

  : $347.37 million versus the three-analyst average estimate of $351.67 million. The reported number represents a year-over-year change of +5.2%.

• Revenue- CAG-Rapid assay products

  : $103.29 million compared to the $100.59 million average estimate based on three analysts. The reported number represents a change of +6.1% year over year.

View all Key Company Metrics for Idexx here>>>

Shares of Idexx have returned -5.9% over the past month versus the Zacks S&P 500 composite's -6.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.